Acetylcysteine therapy for chronic hepatitis C. Are its effects synergistic with interferon alpha? A pilot study

Clinical Drug Investigation

Volumn 16, Issue 4, 1998, Pages 297-302

  Tripi, S ^a   Di Gaetano, C ^a   Soresi, M ^a   Carroccio, A ^a   Bonfissuto, G ^a   Savi, A ^a   Vuturo, O ^a   Montalto, G ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Cattedra di Medicina Interna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; LYMPHOBLAST INTERFERON; MUSCARINIC AGENT; RECOMBINANT ALPHA INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DRUG POTENTIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS REPLICATION;

EID: 0031772492     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816040-00004     Document Type: Article

References (25)

1. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347-56
2. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-89
3. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6
4. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alpha-2b regimens for long-term treatment of chrome non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-62
5. Reichard O, Norkraus G, Fryden A, et al. Randomized, double blind, placebo-controlled trial of interferon alpha 2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351 (1): 83-7
6. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with R and IFN-alpha in IFN-alpha relapsers and NR: Italian experience. J Hepatol 1995; 23 Suppl.: 13-6
7. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patients from European centers. J Hepatol 1997; 26: 961-6
8. Tripi S. Di Gaetano G, Soresi M, et al. Ribavirin and alpha-interferon in patients with chronic hepatitis C not responding to interferon alpha alone. Dig Dis Sci 1998. In press
9. Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of serum hepatitis C virus in patients with chronic hepatitis C treated with interferon beta. Hepatology 1993; 18: 1311-25
10. Montalto G, Tripi S, Cartabellotta A, et al. Intravenous natural beta-interferon in Caucasian patients with chronic hepatitis C non-responders to alpha interferon. Am J Gastroenterol 1998; 93: 950-3
11. Chayma K, Toubota A, Kobayashi M, et al. A pilot study of corticosteroid priming tor lymphoblastoid IFN in patients with CHC. Hepatology 1996; 23: 953-7
12. Boucher E, Jouanolle H, Andre P, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. Hepalology 1995; 21: 322-7
13. Keays R, Harrison PM, Wendom JA, et al. Intravenous acetyl cysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303: 1026-8
14. Holoye PY, Duelge J, Hansen RM, et al. Prophylaxis of isofosfamide toxicity with oral acetyl cysteine. Semin Oncol 1983; 10 Suppl. 1:66-71
15. Scheffner AL. The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent NAC. Ann NY Acad Sci 1983; 106: 298-310
16. Beloqui O, Prieto J, Suarez M, et al. n-Acetyl cisteine enhances the response to alpha-interferon in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279-82
17. Giannini C, Thiers V, Nousbaum JB, et al. Comparative analysis of two assays for genotyping hepatitis C virus (HCV) based on genotype-specific primers of probes. J Hepatol 1995; 23: 246-53
18. Kwok S, Higuchi R. Avoiding false positive results with PCR. Nature 1989; 339: 237-8
19. Roederer M, Staal FJ, Raju PA, et al. Cytokine-stimulaled human immunodeficiency virus replication is inhibited by N-acetyl-l-cysteine. Proc Natl Acad Sci USA 1990; 87: 4884-8
20. Kalebic T, Kinter A, Poli G, et al. Suppression of HIV expression in chronically infected monocytic cells hy glutathione, glutathione ester and N-acelylcysteine. Proc Natl Acad Sci USA 1991; 88 (31): 986-90
21. Pistello M, Maggi F, Vatteroni L, et al. Prevalence of hepatitis C virus genotypes in Italy. J Clin Microbiol 1994; 32: 232-4
22. Pontisso P, Ruvoletto MG, Nicoletti M, et al. Distribution of three major hepatitis C virus genotypes in Italy. A multicenter study of 495 patients with chronic hepatitis C. J Viral Hepatitis 1995; 2: 33-8
23. Pozzato G, Moretti M, Franzin F, et al. Severity of liver disease with different HCV clones. Lancet 1991; 338: 509
24. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum HCV-RN A levels and HCV genotype are the main independent prognostic factors of sustained response to alpha-interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6
25. Montalto G, Zignego AL, Ruggeri MI, et al. Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases. Dig Dis Sci 1997; 42: 1703-7